Battaglia Mario, Kobelt Gisela, Ponzio Michela, Berg Jenny, Capsa Daniela, Dalén Johan
Scientific Research Area, Italian Multiple Sclerosis Foundation (FISM), Genoa, Italy/Department of Life Sciences, The University of Siena, Siena, Italy.
European Health Economics, Mulhouse, France.
Mult Scler. 2017 Aug;23(2_suppl):104-116. doi: 10.1177/1352458517708176.
In order to estimate the value of interventions in multiple sclerosis (MS) - where lifetime costs and outcomes cannot be observed - outcome data have to be combined with costs. This requires that cost data be regularly updated.
This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015.
A total of 1010 patients (mean age = 45 years) participated in Italy. In total, 94% were below retirement age, and of these, 56% were employed. Employment was related to disability, and MS affected productivity at work in 77% of the patients. Overall, 96% and 65% of the patients experienced fatigue and cognitive difficulties as a problem, respectively. Mean utility and total annual costs were 0.735 and €22,900 at Expanded Disability Status Scale (EDSS) of 0-3, 0.534 and €40,100 at EDSS of 4-6.5, and 0.135 and €53,300 at EDSS of 7-9. The mean cost of a relapse was estimated to be €2600.
This study illustrates the burden of MS on Italian patients and provides current data on MS that are important for the development of health policies.
为了评估针对多发性硬化症（MS）的干预措施的价值（在这种疾病中，无法观察到终身成本和结果），必须将结果数据与成本相结合。这就要求定期更新成本数据。
本研究是一项在16个国家开展的横断面回顾性研究的一部分，该研究收集了MS患者的资源消耗、工作能力、健康相关生活质量（HRQoL）和常见症状的数据。从社会角度，按严重程度水平以2015年欧元呈现描述性分析结果。
意大利共有1010名患者（平均年龄 = 45岁）参与研究。总体而言，94%的患者未达到退休年龄，其中56%的患者受雇工作。就业与残疾状况相关，77%的患者的MS影响了其工作效率。总体而言，分别有96%和65%的患者将疲劳和认知困难视为问题。在扩展残疾状态量表（EDSS）为0 - 3时，平均效用和年度总成本分别为0.735和22,900欧元；在EDSS为4 - 6.5时，分别为0.534和40,100欧元；在EDSS为7 - 9时，分别为0.135和53,300欧元。复发的平均成本估计为2600欧元。
本研究说明了MS对意大利患者的负担，并提供了有关MS的当前数据，这些数据对于卫生政策的制定至关重要。
